Inspra

Long-lasting postoperative macular edema is a therapeutic challenge. The authors report an efficient combination therapy of oral… (More)

To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in… (More)

Eplerenone (Inspra) is an aldosterone receptor antagonist approved for the treatment of hypertension and heart failure after a… (More)

Eplerenone (Inspra, Pfizer, New York, USA), a 9,11epoxy derivative of spironolactone, is the second aldosterone antagonist… (More)

Eplerenone (Inspra) is a selective aldosterone blocker. When added to standard medical therapy, eplerenone significantly improved… (More)

Eplerenone is the second oral aldosterone antagonist available in the USA for the treatment of essential hypertension and heart… (More)

Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have… (More)

 

The classical mineralocorticoid effect of aldosterone on unidirectional transepithelial sodium transport in the kidney was long… (More)

Since neither angiotensin-converting enzyme inhibitors (ACE-I) nor angiotensin II receptor blockers (ARB) can completely suppress… (More)